The invention provides compositions including stabilized multilamellar lipid vesicles having crosslinked lipid bilayers (referred to herein as interbilayer-crosslinked multilamellar vesicles or ICMV) and including an ALK variant, pharmaceutical compositions containing vesicles (e.g., ICMV) including an ALK variant, and methods of treatment using such compositions. The invention provides compositions including stabilized multilamellar lipid vesicles with crosslinked lipid bilayers (e.g., an interbilayer-crosslinked multilamellar vesicle or ICMV) containing an Anaplastic lymphoma kinase (ALK) variant as an antigen that is associated with solid tumor cancers.

Provided herein are T-cell receptor (TCR) fusion proteins (TFPs), T-cells engineered to express one or more TFPs, and methods of use thereof for the treatment of diseases, including cancer.

Fusion peptide, and pharmaceutical composition containing the same, for use in treating, preventing and/or delaying the onset of a fibroproliferative vascular disease, wherein the fusion peptide comprises: (a) an amino acid sequence as defined in SEQ ID No.: 1 or a related homolog having at least 85% similarity with SEQ ID No.: 1 and having the ability of the sequence SEQ ID No.: 1 to inhibit the kinase-independent function of PI3Kγ, and (b) a peptide having the ability to penetrate a cell.

The invention relates to self-assembling proteins that are capable of being used to deliver cargo proteins to phagocytic cells, and the subsequent delivery and utility of these self-assembling proteins by the phagocytic cells at sites of disease. In particular, the invention relates inter alia to phagocytic cells comprising polyhedrin protein crystals, wherein the crystals themselves encapsulate therapeutic and/or diagnostic proteins. The invention also provides therapies using these cells.

The present disclosure relates generally to stapled peptides, and pharmaceutical compositions thereof, which are useful for preventing and/or treating herpes simplex virus-1 (HSV-1) processive DNA synthesis, propagation, and/or infection in a subject. The present disclosure further provides methods for treating herpes simplex keratitis in a subject

The invention relates to anti-inflammatory peptides, to pharmaceutical compositions comprising same and to uses thereof for treatment of inflammation including, but not limited to inflammation associated with immune activation.

Disclosed herein are methods for generating universal MHC/HLA-compatible hematopoietic progenitor cells and methods for generating custom patient-specific MHC/HLA-compatible hematopoietic progenitor cells. Compositions comprising the universal and custom hematopoietic progenitor cells and therapeutic applications thereof are also disclosed.

The present application provides SOX9 inhibitor compounds and compositions and methods of use thereof. In certain aspects, the SOX9 inhibitor is a peptide comprising a portion of the SOX9 dimerization motif. In other aspects, the SOX9 inhibitor is a compound of the general formula I

##STR00001##

where one A is H and the other is:

##STR00002##

and the remaining substituents are as defined in the application.

The present invention relates to a cell-penetrating peptide dimer comprising: a first peptide domain consisting of the amino acid sequence of SEQ ID NO: 1; a second 30Kc19α peptide domain consisting of the amino acid sequence of SEQ ID NO: 1; and a peptide linker connecting the first and second peptide domains, a method for preparing the peptide dimer, a cargo delivery system in which a cargo is conjugated to the dimer; and a use thereof. The cell-penetrating peptide dimer according to the present invention may have excellent cell-penetrating properties, thereby being usefully employed as the cargo delivery system.

Degradation compounds include a cyclic cell penetrating peptide (cCPP) and a degradation construct. The degradation construct includes a degradation moiety and a targeting moiety. The targeting moiety binds a target protein. When the targeting moiety is bound to the target protein, the degradation moiety mediates degradation of the target protein. The cCPP facilitates transfer of the degradation construct into a cell. The degradation compound may further include an exocyclic peptide to enhance endosomal escape of the compound or degradation construct once inside the cell.